PharmaEssentia - Public Comps and Valuation Multiples

PharmaEssentia Overview

About PharmaEssentia

PharmaEssentia Corp is engaged in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug pattern developments. It focuses on Hematology, Oncology, and Infectious Diseases. The company derives its revenue from the sales of medicine products. Geographically, the company generates maximum revenue from America, followed by Europe, Asia (excluding Taiwan), and Taiwan.

Founded

2000

HQ

Employees

350

Website

pharmaessentia.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $485M

LTM EBITDA $160M

EV

$7.0B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

PharmaEssentia Financials

As of January 2026, PharmaEssentia reported last 12-month revenue of $485M and EBITDA of $160M.

In the same period, PharmaEssentia generated $430M in LTM gross profit and $164M in net income.

See PharmaEssentia valuation multiples based on analyst estimates

PharmaEssentia P&L

In the most recent fiscal year, PharmaEssentia reported revenue of $308M and EBITDA of $107M.

PharmaEssentia expects next 12-month revenue of XXX and NTM EBITDA of XXX

See PharmaEssentia valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$485M	XXX	$308M	XXX	XXX	XXX
Gross Profit	$430M	XXX	$271M	XXX	XXX	XXX
Gross Margin	89%	XXX	88%	XXX	XXX	XXX
EBITDA	$160M	XXX	$107M	XXX	XXX	XXX
EBITDA Margin	33%	XXX	35%	XXX	XXX	XXX
EBIT	$157M	XXX	$55.0M	XXX	XXX	XXX
EBIT Margin	32%	XXX	18%	XXX	XXX	XXX
Net Profit	$164M	XXX	$93.9M	XXX	XXX	XXX
Net Margin	34%	XXX	30%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for PharmaEssentia including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $485M. EBITDA for the last twelve months was $160M. In the most recent fiscal year, PharmaEssentia achieved $308M in revenue and $107M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$485M	Analyst estimates available to subscribers	$308M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$430M	Analyst estimates available to subscribers	$271M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	88.6% gross margin	Analyst estimates available to subscribers	87.9% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$160M	Analyst estimates available to subscribers	$107M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	33.1% EBITDA margin	Analyst estimates available to subscribers	34.8% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$157M	Analyst estimates available to subscribers	$55.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	32.4% EBIT margin	Analyst estimates available to subscribers	17.8% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$164M	Analyst estimates available to subscribers	$93.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	33.8% net profit margin	Analyst estimates available to subscribers	30.5% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for PharmaEssentia

This financial data table provides comprehensive performance metrics for PharmaEssentia, a company based in Taiwan. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

PharmaEssentia generated $485M in revenue over the last twelve months.
The company achieved $160M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $430M.
Net income over the last twelve months reached $164M.

Fiscal Year Performance

In the most recent fiscal year, PharmaEssentia reported $308M in total revenue.
Fiscal year EBITDA was $107M.
The company maintained a gross profit margin of 87.9% in the most recent fiscal year.
EBITDA margin for the fiscal year was 34.8%.
Net profit margin reached 30.5% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for PharmaEssentia. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

PharmaEssentia Stock Performance

PharmaEssentia has current market cap of TWD 242B (or $7.7B), and EV of TWD 222B (or $7.0B).

Market Cap Evolution

PharmaEssentia Stock Data

As of February 20, 2026, PharmaEssentia's stock price is TWD 725 (or $23).

See PharmaEssentia trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$7.0B	$7.7B	XXX	XXX	XXX	XXX	$0.44

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

PharmaEssentia Valuation Multiples

PharmaEssentia's trades at 14.5x EV/Revenue multiple, and 43.7x EV/EBITDA.

See valuation multiples for PharmaEssentia and 15K+ public comps

PharmaEssentia Financial Valuation Multiples

As of February 20, 2026, PharmaEssentia has market cap of $7.7B and EV of $7.0B.

Equity research analysts estimate PharmaEssentia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

PharmaEssentia has a P/E ratio of 46.8x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$7.7B	XXX	$7.7B	XXX	XXX	XXX
EV (current)	$7.0B	XXX	$7.0B	XXX	XXX	XXX
EV/Revenue	14.5x	XXX	14.5x	XXX	XXX	XXX
EV/EBITDA	43.7x	XXX	43.7x	XXX	XXX	XXX
EV/EBIT	44.6x	XXX	44.6x	XXX	XXX	XXX
EV/Gross Profit	16.3x	XXX	n/a	XXX	XXX	XXX
P/E	46.8x	XXX	46.8x	XXX	XXX	XXX
EV/FCF	42.2x	XXX	42.2x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get PharmaEssentia Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

PharmaEssentia Margins & Growth Rates

PharmaEssentia's last 12 month revenue growth is 45%

PharmaEssentia's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.6M for the same period.

PharmaEssentia's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

PharmaEssentia's rule of X is 147% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for PharmaEssentia and other 15K+ public comps

PharmaEssentia Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	45%	XXX	43%	XXX	XXX	XXX
EBITDA Margin	33%	XXX	33%	XXX	XXX	XXX
EBITDA Growth	90%	XXX	n/a	XXX	XXX	XXX
Rule of 40	32%	XXX	78%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	147%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.9M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.6M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	25%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	27%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	70%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial